Therapeutic analysis of amiodarone use in the treatment of arrhythmogenic right ventricular dysplasia

Abstract

The present study aimed to conduct a comprehensive analysis of amiodarone use in the treatment of arrhythmogenic right ventricular dysplasia (ARVD), a complex and potentially lethal cardiac condition. The rationale for this study lies in the need to clarify the controversies in the literature regarding the efficacy and safety of amiodarone, comparing it with other available therapeutic options. The methodology adopted was a literature review that included clinical data and comparative studies on the use of amiodarone. Parameters such as efficacy in preventing ventricular arrhythmias, impact on quality of life, incidence of adverse effects, and mortality were analyzed. The research used academic and scientific databases to select relevant studies in Portuguese and English, such as Google Scholar and SciELO. The results highlight that amiodarone is widely used due to its proven ability to suppress ventricular arrhythmias, although its prolonged use is associated with significant side effects. Reviewed studies suggest that, despite controversies regarding its superiority over other therapies, amiodarone remains a viable option for initial management of ARVD, especially when combined with other interventions such as beta-blockers and implantable cardioverter-defibrillators. In conclusion, this therapeutic analysis provides a comprehensive overview of the role of amiodarone in the treatment of ARVD, emphasizing the need for rigorous monitoring and an individualized approach to maximize therapeutic benefits and minimize associated risks.